RNA剪接
癌症研究
造血
生物
促炎细胞因子
骨髓增生异常综合症
祖细胞
拼接因子
细胞生物学
信号转导
免疫学
干细胞
组蛋白
RNA结合蛋白
甲基化
川地34
选择性拼接
髓样
髓系白血病
表观遗传学
转录组
DNA甲基化
信使核糖核酸
白血病
细胞粘附
祖细胞
染色质
背景(考古学)
细胞粘附分子
小干扰RNA
抑制因子
核蛋白
核糖核酸
利基
基因
癌变
转录因子
染色质重塑
肿瘤坏死因子α
遗传学
作者
Zi-Juan Li,Mu-ying Zhao,Roujia Wang,Na Liu,Cheng-Long Hu,Binhe Chang,Fang Hu,Xi-Ya Li,Chunhui Xu,Ping Liu,Bing-Yi Chen,Shu-Bei Chen,Yong Wang,Qijing Li,Bu-Sheng Xue,Chuhan Deng,Xinchi Chen,Yiyi Ren,Jiacheng Jin,Xiao Yan
标识
DOI:10.1126/scitranslmed.adv1065
摘要
Patients with myelodysplastic syndrome (MDS) harboring SRSF2 (serine and arginine rich splicing factor 2) mutations exhibit poor prognosis and aberrant inflammatory activation, underscoring an urgent need for therapies. Here, we reveal that low messenger RNA expression of SETD2 ( SET domain containing 2 ) in hematopoietic stem and progenitor cells (HSPCs) from patients with MDS carrying SRSF2P95 mutations (SRSF2 P95-Mut MDS) correlates with adverse outcomes and increased inflammation. Multivariate analysis confirmed the correlation between low SETD2 expression and poor prognosis in patients with SRSF2 P95-Mut MDS. Furthermore, Setd2 loss in the Srsf2 P95H/+ mouse model resulted in lethal MDS with hyperinflammation and expansion of myeloid-derived suppressor cells (MDSCs). Mechanistically, SETD2 methylates SRSF2 P95H at lysine-17 and lysine-65 to inhibit aberrant splicing of CEACAM1-4 (isoforms of carcinoembryonic antigen cell adhesion molecule ), which enhances interleukin-1β (IL-1β) signaling through Slc7a11 (solute carrier family 7 member 11)–mediated cystine uptake, thereby promoting HSPC differentiation into MDSCs, establishing an IL-1β–driven immunosuppressive microenvironment. These findings identify the SRSF2 P95H K17 me1 K65 me2 –CEACAM1-4 signaling axis as a promising therapeutic target in SRSF2 P95-Mut MDS.
科研通智能强力驱动
Strongly Powered by AbleSci AI